Mangoceuticals, Inc.MGRXNASDAQ
Loading
MGRX Revenue Growth (YoY Quarterly)•-36.83%
Stock Alarm Pro
Growth Metrics
Latest: Q3 2025vs Q2 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-36.83%
-39.9pp
-38.43%
-67.3pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+472.25%
-1.5pp
+472.25%
-1.5pp
+0.00%
+0.0pp
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -45.60% | -56.93% | -48.95% | +3.03% | -36.83% |
| Gross Profit Growth | -42.82% | -43.82% | -57.89% | +28.88% | -38.43% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +89.63% | +150.05% | +201.78% | +473.77% | +472.25% |
| Weighted Average Shares Diluted Growth | +89.63% | +150.05% | +201.78% | +473.77% | +472.25% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | -38.77% | -100.00% | -100.00% | -100.00% | -100.00% |
| Asset Growth | +827.11% | +1362.75% | +7116.48% | +36.78% | +11.76% |
| Book Value per Share Growth | +421.17% | +619.89% | +0.00% | -75.75% | -79.47% |
| Debt Growth | +87.56% | +67.05% | -76.23% | +121.06% | -21.13% |
| R&D Expense Growth | +0.00% | -52.49% | +0.00% | +0.00% | -100.00% |
| SG&A Expenses Growth | -6.09% | +35.37% | +115.24% | +138.92% | -73.75% |
1 / 3